Zymeworks Inc.
ZYMEHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeZymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. With a market capitalization of $1.81B, it sits in small-cap territory. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Market Cap
$1.81B
Beta
1.13
P/E (TTM)
—
P/E (Fwd)
86.83
EPS (TTM)
$-1.37
EPS (Fwd)
$0.28
ROE
-42.0%
ROA
-15.8%
Cash
$364.7M
Total Debt
$17.0M
Free CF
-$45.5M
52W Change
82.4%
Annual Financials
Cash vs Debt
Zymeworks Inc. holds $364.7M in cash against $17.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$45.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -42.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $412.5M to $106.0M.
With cash comfortably exceeding debt, ZYME has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZYME.